Sacubitril/Valsartan
- Generic Name
- Sacubitril/Valsartan
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
⑴用于在有慢性心力衰竭(NYHA类别II-IV)患者中减低对心力衰竭的心血管死亡及住院治疗慢性心力衰竭和射血分数降低。本品通常与其他心力衰竭治疗结合，代替一种ACE抑制药或其他血管紧张素II受体阻断药。
⑵用于治疗原发性高血压.
- Associated Conditions
- -
- Associated Therapies
- -
Sacubitril/Valsartan for CKD5 Stage Dialysis Patients
- Conditions
- Interventions
- First Posted Date
- 2022-02-16
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 330
- Registration Number
- NCT05243199
- Locations
- 🇨🇳
Department of Nephrology, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, Shanghai, China
Efficacy and Safety of Sacubitril/Valsartan in African American Patients With Heart Failure With Reduced Ejection Fraction
- Conditions
- First Posted Date
- 2021-12-23
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Methodist Health System
- Target Recruit Count
- 352
- Registration Number
- NCT05168787
- Locations
- 🇺🇸
Methodist Dallas Medical Center Pharmacy, Dallas, Texas, United States
Role of Sacubitril/Valsartan in Improving Provider Performance in Managing Heart Failure Under Medicare Alternative Payment Models
- Conditions
- Interventions
- First Posted Date
- 2021-10-27
- Last Posted Date
- 2021-12-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1614719
- Registration Number
- NCT05096039
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
A Cohort Study to Compare the Hospitalization Between Naive Sacubitril/Valsartan and Naive ACEi/ARBs Heart Failure Patients With Reduced Ejection Fraction Using Secondary US Electronic Health Records Data
- First Posted Date
- 2021-10-27
- Last Posted Date
- 2021-12-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 42269
- Registration Number
- NCT05096143
- Locations
- 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States
Sacubitril/Valsartan Versus Amlodipine in Hypertension and Left Ventricular Hypertrophy.
- Conditions
- Interventions
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 120
- Registration Number
- NCT04929600
- Locations
- 🇨🇳
Shanghai Institite of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Effect of LCZ696 on Urinary Microalbumin and Pulse Wave Velocity in Perimenopausal Patients With Hypertension
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2021-03-16
- Lead Sponsor
- LanZhou University
- Target Recruit Count
- 264
- Registration Number
- NCT04800081
- Locations
- 🇨🇳
Department of Cardiology, Second Hospital of Lanzhou University, Lanzhou, GuSu, China
Prospective Monitoring of Angiotensin Receptor Neprilysin Inhibitor in Older Adults With Heart Failure and Frailty
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2021-02-15
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 40000
- Registration Number
- NCT04743063
- Locations
- 🇺🇸
Brigham And Women's Hospital, Boston, Massachusetts, United States
Replication of the PARADIGM-HF Heart Failure Trial in Healthcare Claims Data.
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 6066
- Registration Number
- NCT04736433
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction Patients: a Real World Study in India
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 268
- Registration Number
- NCT04735354
- Locations
- 🇮🇳
Novartis Investigational Site, Mumbai, India
Open-label Extension Study for CLCZ696G2301 (PARADISE-MI)
- First Posted Date
- 2020-11-19
- Last Posted Date
- 2021-11-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04637555
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.